Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of JW1601 in Healthy Volunteers
NCT04018170Phase 1Completed
- Sponsor
- JW Pharmaceutical Corporation
- Start
- Feb 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in atopic dermatitis (AD) comparing JW1601 (Izuforant) with Placebo (2 arms). Primary endpoints: Safety and tolerability after single ascending dose administration at Day 8 and Safety and tolerability in multiple ascending dose administration at Day 14. Started Feb 2019; status: completed.
02
Drugs
JW1601
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04018170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04018170.